April 6th 2023, from 10:00 am to 1:00 pm
Brain Institute Auditorium, Paris
Continuous and rapid scientific progress has over the past few years been transforming medical practice by accelerating the translations between burgeoning scientific research and rapidly developing precision
medicine. Knowledge in molecular biology, combined with increased computing and imaging capabilities, is leading to a new era in which genetic diseases and personal susceptibilities to disease are becoming both predictable and exploitable for the diagnosis, monitoring and treatment of most known diseases and conditions.
Thus, biomarker discovery, gene and cell therapies and genome editing (Crispr) are helping to define new prophylactic means, new therapeutic vaccines, new definitive curative treatments, new transplantation modalities. This by directly and permanently modifying deleterious base mutations or disrupting disease-causing genes with great precision and efficiency.
The drug industry will also be transformed, from mass-produced drugs resulting from serendipity-driven
research to a totally different industry. Thanks to the knowledge of molecular mechanisms (made possible by machine-learning combined with the ability to induce exploratory perturbations by stimulating or extinguishing the various genomic sequences), this new industry will be able to design a large number of drugs with specific and personalized therapeutic targets.
Transforming these inventions and discoveries into innovations available to patients is like moving from an art to an industry. This implies the presence of innovative companies and the mobilization of the entire ecosystem “from molecule to society” and our ability to collectively address several ethical, industrial, educational, medical and economic issues that will make us either victims or players in this coming revolution.
E4i is a not-for-profit partnership organization dedicated to innovation in the field of precision medicine and women’s health. Its purpose is to help ensure that we can be as active as possible in these transformations for the benefit of patients.
PROGRAM
Welcome and introduction: why an ecosystem for innovation
- Yahya El Mir, Founder and President of Ziwig
Therapeutics related to precision medicine
- Nicolas Levy, Professor of Medical Genetics, Scientific Director of Rare Diseases, Servier
Round table discussion
- Alexandre Paix, Genomics Engineer, EMBL, Heidelberg
- Benoît Maisonneuve, Product Owner Clinical Translation, NETRI
- Alex Templier, Engineer, CEO of Quinten
- Jean-Claude Gerard, VP HTG molecular diagnostics
- Chiraz Khayat, Director, Instrument product management, DNA script
- Judith Michels, Medical Oncology, IGR Translational Research Laboratory, Paris
- Sophie Le Ricousse, Head of Biology, Transfer and Innovation Department, INCA, Paris
- Michel Tsimaratos, Professor of Paediatrics, Deputy Director General of the biomedicine agency, Paris
- Peter Winter, Science and Technology Sociologist, University of Bristol
- Yosr Hamdi, Professor of oncology, Pasteur Institut, Tunis
Conclusion
- Hervé Chneiweiss, CNRS Research Director, neuro-oncologist, Director of the Neuroscience Paris Seine Laboratory, President of the Inserm Ethics Committee and of the Research Committee of the Foundation for Medical Research.